PhD Dr Shadli has a diverse background in Cognitive Neuropsychology and has worked in the mental health area, especially anxiety and depression. He completed his PhD (An improved human anxiety-specific biomarker: Frequency band, modality specificity, personality, pharmacology, and source characterisation) in 2015 under the supervision of Professor Neil McNaughton in the Department of Psychology, University of Otago, New Zealand. Dr Shadli worked at the University of Otago as a postdoctoral and research fellow from 2015-2022. I had almost 7 years of academic experience in the Department of Psychology, University of Otago. Before joining CSU, he worked as a Lecture in Neuroscience at the University of New England, Australia from 2022-2023. His current h-index is 9 and i-10 index is 9. He is currently involved in teaching PSY421 Psychological Interventions at the School of Psychology, CSU. Before joining Charles Sturt, He was a Lecturer in Neuroscience at the University of New England teaching 4 separate units (NEUR501: Research Topics in Neuroscience: In teaching these units, he used the DSM5-TR manual to help his students learn about the diagnostic criteria, symptoms and associated features of a particular mental disorder. He also taught them about the neurobiology, genetics, and environmental risk factors of the disorders; and about the currently available biological and psychological treatments. BLURB on CSU position. Dr Shadli uses a range of methods including EEG, fMRI and source localization (sLORETA) together with pharmacological interventions. The laboratory in which he did his PhD developed the first biomarker for any anxiety disorder; and his PhD developed an improved form of this biomarker suitable for use in the clinic. Dr Shadli has continued to develop this; and is now also involved in finding a new treatment for treatment-resistant (TR) anxiety and depression – using, off label, the drug ketamine to treat TR patients with neurotic disorders. His current work involves a search for a response biomarker to understand the mechanism of action of ketamine using EEG, fMRI and blood samples, supported by two separate project grants from The Health Research Council of NZ. His research goal is to better understand the pathophysiology of anxiety and depressive disorders, their comorbidity, and their potential treatment.
Professors and Lecturers
Dr Shabah Shadli
Lecturer
Bathurst
Building 1400, Room 231
Teaching
Research